Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. (Q36509293)

14 August 2017

Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. (English)

1 reference

14 August 2017

Neeraj Dhaun

1

1 reference

14 August 2017

Vanessa Melville

2

1 reference

14 August 2017

Scott Blackwell

3

1 reference

14 August 2017

Dinesh K Talwar

4

1 reference

14 August 2017

Neil R Johnston

5

1 reference

14 August 2017

Jane Goddard

6

1 reference

14 August 2017

David J Webb

7

1 reference

14 August 2017

14 December 2012

1 reference

Journal of the American Society of Nephrology

14 August 2017

1 reference

14 August 2017

24

1 reference

14 August 2017

1

1 reference

14 August 2017

31-36

1 reference

The role of asymmetric and symmetric dimethylarginines in renal disease

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Regulation of blood pressure and salt homeostasis by endothelin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Chronic kidney disease: effects on the cardiovascular system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Causes and consequences of increased arterial stiffness in chronic kidney disease patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

The endothelin system and its antagonism in chronic kidney disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Chronic kidney disease: the global challenge

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Impact of aortic stiffness on survival in end-stage renal disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

New enzymatic method for serum uric acid at 500 nm

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pu

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3537212

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

4 December 2018

1 reference

12 December 2020

Uric acid and cardiovascular risk

1 reference

12 December 2020

Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease

1 reference

12 December 2020

Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease

1 reference

12 December 2020

Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity

1 reference

12 December 2020

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial

1 reference

12 December 2020

Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey

1 reference

12 December 2020

Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure

1 reference

12 December 2020

Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine

1 reference

12 December 2020

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2012040355

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

23243212

1 reference